Home › Funds › Amplify ETF Trust › Amplify Weight Loss Drug & Treatment ETF
Fund family: Amplify ETF Trust · Filed by Amplify ETF Trust (CIK 1633061) · SEC series S000085024
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 212 with, 8 against, 5 abstentions (not counted as with management). Shareholder proposals: 4 FOR, 4 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as Amplify ETF Trust’s manager page (13,713 ballot items across 28 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | Amplify ETF Trust | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 74.2% | 186 | 70.4% | 11,728 |
| Backed environmental and social shareholder proposals at US companies | n/a | 4 | 3.8% | 342 |
Each ballot item this fund voted is set against the votes of the other Amplify ETF Trust funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted the same way as most Amplify ETF Trust funds on all 36 items where a comparison was possible.
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 130 | 0 |
| Corporate Governance | 23 | 4 |
| Capital Structure | 17 | 0 |
| Audit-related | 16 | 0 |
| Say-on-Pay | 12 | 0 |
| Compensation | 11 | 0 |
| Other | 10 | 0 |
| Other Social Issues | 3 | 2 |
| Human Rights or Human Capital/workforce | 2 | 2 |
| Shareholder Rights and Defenses | 1 | 0 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| ELI LILLY AND COMPANY | May 4, 2026 | $744,012 | 10 | 2 |
| AMGEN INC. | May 19, 2026 | $410,078 | 15 | 1 |
| REGENERON PHARMACEUTICALS, INC. | June 12, 2026 | $351,436 | 7 | 0 |
| ABBVIE INC. | May 8, 2026 | $276,962 | 8 | 1 |
| MERCK & CO., INC. | May 26, 2026 | $254,789 | 18 | 3 |
| PFIZER INC. | April 23, 2026 | $236,787 | 16 | 1 |
| ARROWHEAD PHARMACEUTICALS, INC. | March 19, 2026 | $100,224 | 10 | 0 |
| SCHOLAR ROCK HOLDING CORPORATION | June 4, 2026 | $89,303 | 6 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 4, 2026 | ELI LILLY AND COMPANY | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | For | Against |
| May 4, 2026 | ELI LILLY AND COMPANY | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | Against | For |
| May 19, 2026 | AMGEN INC. | Stockholder proposal to require an independent board chairman. Shareholder proposal | For | Against |
| May 8, 2026 | ABBVIE INC. | Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposal | For | Against |
| May 26, 2026 | MERCK & CO., INC. | Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposal | Against | For |
| May 26, 2026 | MERCK & CO., INC. | Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposal | Against | For |
| April 23, 2026 | PFIZER INC. | Adopt an Independent Chair Policy Shareholder proposal | For | Against |
225 ballot items at 22 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Amplify Weight Loss Drug & Treatment ETF voted at 22 shareholder meetings of 20 companies, on 225 ballot items in all. Where management made a recommendation, the fund followed it on 94.2% of the items and voted against it 8 times. Its most frequent area of disagreement was corporate governance (4 of its votes against management). It voted on 8 shareholder proposals. It voted FOR the board's own proposals more often than Amplify ETF Trust's funds as a whole (74.2% against 70.4%). It voted the same way as most Amplify ETF Trust funds on every item where a comparison was possible.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Amplify ETF Trust’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.